论文部分内容阅读
目的:观察参芎葡萄糖对中、重度慢性阻塞性肺疾病患者的疗效。方法:采用随机对照研究,参芎葡萄糖组使用参芎葡萄糖注射液,对照组使用5%葡萄糖注射液,观察临床疗效、监测肺功能、血气分析。结果:治疗第3个疗程,参芎葡萄糖组Po2、Dlco较治疗前平均增加了21.4 mmHg、22.7 mL/min/mmHg,二者统计学均有显著差异(P<0.05);改善率:参芎葡萄糖组为22.7%,对照组为0,二者统计学有显著差异(P<0.05)。恶化率:参芎葡萄糖组4.55%,对照组为12%,二者统计学有显著差异(P<0.05)。结论:参芎葡萄糖可降低中、重度COPD患者恶化率,提高改善率,一定疗程后可改善中、重度COPD患者的弥散功能,改善机体缺氧状态。
Objective: To observe the effect of Shenxiong glucose on patients with moderate and severe chronic obstructive pulmonary disease. Methods: A randomized controlled study, Shenxiong glucose group using Shenxiong glucose injection, the control group using 5% glucose injection, observe the clinical efficacy, monitoring of lung function, blood gas analysis. Results: In the third course of treatment, Po2 and Dlco of Shenxiong glucose group increased by 21.4 mmHg and 22.7 mL / min / mmHg on average, respectively (P <0.05); the improvement rate was Glucose group was 22.7%, the control group was 0, the two statistically significant difference (P <0.05). The rate of deterioration was 4.55% in Shenxiong glucose group and 12% in control group, the difference was statistically significant (P <0.05). Conclusion: Shenxiong glucose can reduce the exacerbation rate of moderate and severe COPD patients and improve the rate of improvement. After a certain course of treatment, it can improve the diffusing function of moderate and severe COPD patients and improve the hypoxia state.